Evidence-linked professional biography
Academic & Professional Profile — Dr Zool Hilmi Awang
Full professional name: Dr Zool Hilmi Bin Awang
Malaysian Consultant Nuclear Medicine Physician whose work spans molecular imaging, targeted radionuclide therapy, peer-reviewed PSMA research and the development of nuclear medicine services across public and private healthcare.
Current appointmentHead & Consultant in Nuclear MedicineTunku Laksamana Johor Cancer Centre
Who is Dr Zool Hilmi?
A career connecting clinical medicine, research and service building.
Dr Zool Hilmi Bin Awang is a Malaysian Consultant Nuclear Medicine Physician based in Johor Bahru. He trained in Malaysia, Indonesia, Germany and the United States, and has contributed to PET/CT, SPECT/CT and theranostic services including Lu-177 PSMA, PRRT, Y-90 SIRT and radioactive iodine.
His professional record includes public service at Hospital Kuala Lumpur, Sarawak General Hospital and Institut Kanser Negara; leadership of the Nuclear Medicine Department at Thomson Hospital Kota Damansara; and his current role developing molecular imaging and nuclear medicine at Tunku Laksamana Johor Cancer Centre.
Verification approach: completed achievements are linked to official registries, institutional records, PubMed or primary documents. Future facilities are explicitly labelled as planned and subject to approval and commissioning.
Academic & professional timeline
From medical school to Johor theranostics.
Each milestone includes the strongest available source type. Source links open the original registry, institutional record, journal record or primary archive.
Doctor of Medicine, Universitas Hasanuddin
Makassar, Indonesia
Completed the six-year medical programme and graduated in 2002. The Malaysian Medical Council record confirms the MD qualification and Universitas Hasanuddin as the awarding institution.
Master of Medicine in Nuclear Medicine
Universiti Sains Malaysia & Hospital Kuala Lumpur
Undertook postgraduate specialist training in nuclear medicine, culminating in the Master of Medicine (Nuclear Medicine) qualification in 2013. His thesis evaluated local outcomes after I-131 treatment for hyperthyroidism at Hospital Kuala Lumpur.
Nuclear medicine service development in Sarawak
Sarawak General Hospital, Kuching
Contributed to nuclear medicine service development in Sarawak, including radionuclide therapy and hybrid-imaging capability. A 2016 peer-reviewed paper records his Department of Nuclear Medicine, Sarawak General Hospital affiliation.
From nuclear cardiology to infection imaging
Sarawak General Hospital, Kuching
The official IAEA record lists Dr Zool Hilmi as author and presenter of a 2016 IMIC contribution on MUGA utilisation at Sarawak General Hospital. In January 2017, he was first and corresponding author of a short communication on combined sulphur-colloid and Scintimun imaging to help differentiate osteomyelitis from Charcot joint.
RCA / IAEA regional programme participation
Regional nuclear medicine collaboration
The Regional Cooperative Agreement annual report lists “AWANG, Zool Hilmi” as a Malaysian participant, documenting early engagement in an international nuclear-science cooperation programme.
Advanced theranostic nuclear medicine training in Germany
Zentralklinik Bad Berka & University Hospital Bonn
Completed advanced clinical exposure in theranostic oncology, including PRRT, PSMA radioligand therapy, SIRT and radium-223. The associated Bonn work led directly into peer-reviewed PSMA research with international collaborators.
First-author review of PSMA radioligand therapy
Radiation Oncology
Published a first-author clinical review with Markus Essler and Hojjat Ahmadzadehfar on contemporary approaches to radioligand therapy for metastatic castration-resistant prostate cancer.
Targeted radionuclide therapy training at MD Anderson
Houston, Texas, United States
Completed regional training in targeted radionuclide therapy at The University of Texas MD Anderson Cancer Center, extending earlier theranostic experience gained in Germany.
Initiated Lu-177 PSMA therapy at Institut Kanser Negara
Institut Kanser Negara, Putrajaya
Helped initiate and coordinate a new Lu-177 PSMA treatment pathway for selected patients with metastatic castration-resistant prostate cancer within Malaysia’s government hospital system.
Expert Committee contribution
Ministry of Health Malaysia
Named as the nuclear medicine representative contributing expert input to the Malaysian Health Technology Assessment discussion on hyperthermic intraperitoneal chemotherapy (HIPEC). This is presented as a specific committee contribution, not a broad or permanent appointment.
Established and led Nuclear Medicine at Thomson Hospital
Thomson Hospital Kota Damansara
Served as Head of Nuclear Medicine and helped build an integrated molecular-imaging and theranostic service, including PET/SPECT/CT, I-131, Lu-177 PSMA and multidisciplinary cancer-care pathways.
Head & Consultant in Nuclear Medicine at TLJCC
Tunku Laksamana Johor Cancer Centre, Johor Bahru
Leads the development of molecular imaging and nuclear medicine at TLJCC, connecting PET/CT and future targeted radionuclide therapy with an integrated cancer-care pathway.
Cyclotron, radiopharmaceuticals & theranostics
Tunku Laksamana Johor Cancer Centre
Contributing to the planned Johor cyclotron and nuclear medicine programme intended to strengthen regional access to PET radiopharmaceuticals and advanced theranostics. The programme remains subject to regulatory approvals, licensing, procurement, validation and operational readiness.
Selected peer-reviewed work
A publication record in theranostics and nuclear oncology.
Author names in the literature may appear as Zool Hilmi Awang, Awang ZH or Z.H. Awang. The links below lead to PubMed, PubMed Central or the journal record.
01
View the complete research archive →Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Radiation Oncology · 13, Article 98
Open original record ↗02Differentiating Osteomylelitis from Charcot Joint by Using Sulphur Colloid and Besilosomab (Scintimun®) Scan at Sarawak General Hospital
Journal of Nuclear Medicine & Radiation Therapy · 8(1):323
Open original record ↗03Predictors of overall survival in patients receiving [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy
Oncotarget · 8:103108–103116
Open original record ↗04Underutilization of MUGA Study at Sarawak General Hospital, Malaysia
IAEA IMIC 2016 · Conference contribution 831
Open original record ↗05A pioneer experience in Malaysia on in-house radio-labelling of ¹³¹I-rituximab
Applied Radiation and Isotopes · 116:13–21
Open original record ↗06Comparison of radiocolloid, blue dye and a combined method for sentinel lymph node biopsy
JUMMEC · Special Issue 1
Open original record ↗Evidence standard
What makes this profile verifiable?
A professional profile is strongest when readers can distinguish an official record, a peer-reviewed publication, a primary document and a future plan. This page uses all four deliberately and labels them at the point of use.
Official registries
Malaysian Medical Council and institutional records for identity, qualification and current practice.
Peer-reviewed records
PubMed, PubMed Central, DOI and journal pages for authorship, affiliation and research contribution.
Primary documents
Graduation, thesis, fellowship and training records retained in the professional archive.
Planned work
Future facilities are labelled “planned” and include regulatory and operational qualifications.
Explore the clinical work